Kopran Ltd

Kopran Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Kopran Ltd

₹ 192 3.24%
21 May - close price
kopran.com BSE: 524280 NSE: KOPRAN
About

Kopran Ltd. is a fully integrated pharmaceutical company that manufactures and supplies high-quality formulations and active pharmaceutical ingredients globally.

Key Points

Business Verticals FY24
1. API Vertical (~54%): WOS Kopran Research Laboratories operates the API vertical. [1] The co. undertakes development, manufacturing, and sale of diverse Active Pharmaceutical Ingredients and Advanced Intermediates. It is one of the leaders in Atenolol. [2]

Website BSE NSE
  • Market Cap ₹ 928 Cr.
  • Current Price ₹ 192
  • High / Low ₹ 370 / 155
  • Stock P/E 24.1
  • Book Value ₹ 107
  • Dividend Yield 1.56 %
  • ROCE 9.75 %
  • ROE 7.64 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has been maintaining a healthy dividend payout of 39.7%

Cons

  • The company has delivered a poor sales growth of 11.9% over past five years.
  • Company has a low return on equity of 8.32% over last 3 years.
  • Company might be capitalizing the interest cost

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Part of BSE Healthcare BSE SmallCap BSE Allcap

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
142.83 125.62 116.97 158.00 148.88 117.00 152.59 158.92 186.08 139.44 151.56 166.24 172.36
116.83 112.46 106.83 145.68 136.72 110.69 129.76 135.34 164.39 121.28 136.83 146.39 155.27
Operating Profit 26.00 13.16 10.14 12.32 12.16 6.31 22.83 23.58 21.69 18.16 14.73 19.85 17.09
OPM % 18.20% 10.48% 8.67% 7.80% 8.17% 5.39% 14.96% 14.84% 11.66% 13.02% 9.72% 11.94% 9.92%
2.06 0.65 0.44 2.22 3.78 2.39 0.13 2.43 9.67 2.63 1.00 0.17 3.26
Interest 1.29 0.79 1.28 2.24 1.78 1.83 1.94 2.24 2.59 2.18 2.23 2.16 2.77
Depreciation 2.69 3.05 3.25 3.16 3.24 3.26 2.77 3.27 3.59 3.87 3.85 4.00 3.87
Profit before tax 24.08 9.97 6.05 9.14 10.92 3.61 18.25 20.50 25.18 14.74 9.65 13.86 13.71
Tax % 27.28% 23.77% 23.14% 23.96% 26.37% 22.99% 24.55% 23.02% 26.01% 24.69% 23.42% 24.96% 29.39%
17.51 7.60 4.65 6.95 8.04 2.77 13.77 15.79 18.62 11.10 7.38 10.40 9.68
EPS in Rs 3.63 1.58 0.96 1.44 1.67 0.57 2.86 3.28 3.86 2.30 1.53 2.16 2.01
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
303 326 296 310 313 358 360 492 478 551 615 630
260 294 266 274 283 312 313 410 390 499 540 557
Operating Profit 43 31 30 36 31 46 47 82 87 52 74 73
OPM % 14% 10% 10% 12% 10% 13% 13% 17% 18% 9% 12% 12%
2 -48 1 11 9 3 -0 18 11 3 15 4
Interest 14 13 13 14 9 9 9 6 5 6 9 9
Depreciation 13 10 8 8 9 9 10 10 11 13 13 16
Profit before tax 17 -39 11 25 23 32 28 83 82 36 68 52
Tax % 0% 0% 0% 20% 10% 24% 26% 26% 25% 24% 25% 26%
17 -39 11 20 20 24 21 62 61 27 51 39
EPS in Rs 4.40 -9.52 2.48 4.60 4.74 5.55 4.86 14.24 12.66 5.65 10.57 7.99
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 21% 24% 53% 28% 38%
Compounded Sales Growth
10 Years: 7%
5 Years: 12%
3 Years: 10%
TTM: 2%
Compounded Profit Growth
10 Years: 10%
5 Years: 12%
3 Years: -14%
TTM: -24%
Stock Price CAGR
10 Years: 14%
5 Years: 47%
3 Years: -5%
1 Year: -21%
Return on Equity
10 Years: 13%
5 Years: 12%
3 Years: 8%
Last Year: 8%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 39 41 43 43 43 43 43 43 48 48 48 48
Reserves 67 49 57 81 101 125 146 202 378 391 443 470
137 86 80 95 89 97 88 66 75 75 99 148
56 99 84 78 82 85 92 128 110 135 153 178
Total Liabilities 299 275 264 298 315 351 370 439 611 650 743 844
105 102 101 104 104 113 111 112 151 165 182 222
CWIP 20 1 3 6 10 24 30 43 36 70 97 99
Investments 1 0 0 0 0 0 0 0 0 0 0 0
174 172 160 187 201 214 229 284 425 415 465 522
Total Assets 299 275 264 298 315 351 370 439 611 650 743 844

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
3 46 29 16 26 25 31 60 -33 34 43 42
-9 -10 -9 -18 -11 -25 -13 -25 -84 -13 -44 -56
7 -37 -19 2 -15 -1 -18 -35 123 -20 1 26
Net Cash Flow 0 -0 0 -0 -0 -0 0 0 5 2 1 11

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 68 91 70 86 75 88 94 89 97 108 126 125
Inventory Days 103 78 119 122 138 129 154 121 202 133 126 153
Days Payable 69 119 115 95 118 90 95 104 84 89 103 108
Cash Conversion Cycle 101 50 74 113 96 127 153 106 215 152 149 170
Working Capital Days 108 67 80 109 121 117 126 113 200 177 180 189
ROCE % 14% 14% 14% 19% 14% 16% 14% 30% 21% 8% 14% 10%

Shareholding Pattern

Numbers in percentages

2 Recently
Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
44.25% 44.25% 44.29% 44.29% 44.49% 44.49% 44.49% 44.49% 44.49% 44.49% 44.45% 44.42%
0.50% 0.51% 0.34% 0.41% 0.34% 0.39% 0.48% 0.84% 0.68% 1.31% 0.86% 1.11%
0.13% 0.14% 0.14% 0.14% 0.14% 0.35% 0.14% 1.20% 0.14% 0.22% 0.00% 0.00%
55.11% 55.09% 55.22% 55.15% 55.03% 54.78% 54.88% 53.47% 54.68% 53.98% 54.68% 54.45%
No. of Shareholders 40,88341,76842,03441,56744,03853,79151,63650,85051,49257,15460,56058,652

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls